KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Systemic chemotherapy remains the main treatment option for malignant tumors, including breast cancer. Nevertheless, the frequent development of resistance in tumors often causes treatment failure and patient death, presenting a significant challenge in cancer treatment.
Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.
Researchers at Stanford have developed a novel method of using macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR) for the treatment or prevention of kinase-mediated disorders, including cancer and other proliferation diseases.
Stanford researchers have discovered that Neat1, a long non-coding RNA, regulates degradation of the MYC protein, revealing a new target for treating MYC-dependent cancers.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).
Researchers at Stanford University have demonstrated rapid and accurate identification of extracellular vesicles (EVs) from different cell lines using an AI-assisted optical platform.
High-grade gliomas, including glioblastoma and diffuse midline glioma are the most common malignant brain tumor types and leading causes of brain-tumor-related death in adults and children, respectively.
Stanford researchers in Prof. Corinne Beinat's lab have developed a novel radiotracer, [18F]hGTS13, for non-invasive imaging of system xc- activity, enabling the identification of ferroptosis-sensitive cancers and monitoring the efficacy of ferroptosis-inducing therapies.
Stanford researchers in Prof. Corinne Beinat's lab have developed a small molecule radiotheranostic for targeted radionuclide therapy of cancers overexpressing system xc-, such as high-grade glioma and non-small cell lung cancer (NSCLC).